AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $45.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$45.7M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $115.92
- 52-wk high
- $126.38
- High
- $120.51
- 52-wk low
- $28.66
- Low
- $113.16
- Prev close
- $115.63
- Mkt cap
- $12.40B
- P/E
- 255.0x
- Volume
- 964.5K
- Fwd P/E
- 19.3x
- Beta
- 0.45
- P/S
- 14.9x
- P/B
- 18.0x
- Profit margin
- +6.6%
- Op margin
- +16.1%
- ROE
- +8.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CORT filings
Are insiders buying or selling Corcept Therapeutics Incorporated (CORT) stock?
Net selling: insiders sold $45.7M and bought $0 of CORT stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $44.4M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Mokari, Atabak (Chief Financial Officer), who sold $12.7M. The latest filing was on Sep 18, 2026.
Which members of Congress have traded CORT recently?
None. No member of Congress disclosed a CORT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CORT smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- AQ
AQR
$208.7M
added
- DS
D.E. Shaw
$41.7M
added
- BO
Bank of America
$24.1M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in CORT right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in $0.40 a share above what analysts expected.
Earnings per share
-$0.04 expected
Reports Nov 3, 2026, in 33 days
Estimates as of Sep 30, 2026
EPS expected
$0.74 to $1.03
Revenue expected
4 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $207.6M | $202.1M | $164.9M | $256.1M |
| Cost of what it sold | $4.6M | $2.5M | $2.9M | $4.1M |
| Gross profit | $203.0M | $199.6M | $162.0M | $252.1M |
| What it spent | ||||
| Research and development | $68.8M | $64.9M | $66.3M | $53.9M |
| Sales and admin | $124.0M | $130.2M | $145.4M | $156.9M |
| Total operating expenses | $192.8M | $195.1M | $211.6M | $210.8M |
| What was left | ||||
| Operating profit | $10.2M | $4.5M | -$49.6M | $41.3M |
| Profit before tax | $15.2M | $9.9M | -$44.7M | $45.9M |
| Tax | -$4.4M | -$14.4M | -$13.5M | -$2.9M |
| Net profit | $19.7M | $24.3M | -$31.2M | $42.1M |
| EBITDA | $15.7M | $10.4M | -$44.1M | $46.8M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Corcept Therapeutics Announces New Endocrinology Division President
BullishSep 25Does EU Ovarian Cancer Backing Change The Bull Case For Corcept Therapeutics Stock?
Leans bullishSep 24Corcept Announces Planned Leadership Transition
Leans bullishSep 23Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires
BullishSep 23Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant
NeutralSep 23Corcept Therapeutics (CORT) oncology president sells shares under 10b5-1 plan
Leans bearishSep 19Corcept Therapeutics (CORT) Dropped, So What Is Behind The Latest Attention?
Leans bullishSep 19Corcept Therapeutics Inc (CORT) Stock Price, Quote, News & History
BullishSep 19